Guggenheim initiates CG Oncology stock with Buy rating, $90 price target
PositiveFinancial Markets

Guggenheim has initiated coverage of CG Oncology with a Buy rating and set a price target of $90. This positive outlook reflects confidence in CG Oncology's potential for growth and success in the market, which could attract investors looking for promising opportunities in the biotech sector.
— Curated by the World Pulse Now AI Editorial System